吡唑并[1,5-a]嘧啶类化合物的合成及其抗肿瘤活性

目的 设计合成新的吡唑并[1,5-a]嘧啶类化合物,并评价其抗肿瘤活性.方法 根据吡唑并[1,5-a]嘧啶类抗肿瘤药物的基本结构设计了一系列5-胺甲基-7-苯胺基吡唑并[1,5-a]嘧啶类化合物,并以丙二腈和原甲酸三乙酯为起始原料,经5步反应得到目标产物.采用MTT法,以顺铂为阳性对照药,以Bel-7402和HT-1080为测试细胞株对目标化合物的抗肿瘤活性进行评价.结果与结论 合成了11个未见文献报道的化合物,结构经质谱和核磁共振氢谱确证.化合物6显示出很好的抗肿瘤活性.     

5,7-二取代吡唑并[1,5-a]嘧啶类化合物的合成及其抗肿瘤活性

目的设计并合成吡唑并[1,5-a]嘧啶类化合物,并评价其抗肿瘤活性。方法根据吡唑并[1,5-a]嘧啶类抗肿瘤药物的基本结构,设计了14个5-胺甲基-7-苯胺基吡唑并[1,5-a]嘧啶类化合物,并以丙二腈和原甲酸三乙酯为起始原料,经5步反应得到目标产物。采用MTT法,顺铂为阳性对照药,以Bel-7402和HT-1080为测试细胞株对目标化合物进行抗肿瘤活性评价。结果与结论合成了14个未见文献报道的新化合物,结构经MS、IR和1H-NMR确证。体外活性实验表明:化合物12显示出较好的抗癌活性。     

[1,2,4]三氮唑并[1,5-a]嘧啶类化合物的合成及其抗肿瘤活性

目的寻找具有抗肿瘤活性的新化合物,设计合成[1,2,4]三氮唑并[1,5-a]嘧啶衍生物,并评价其体外抗肿瘤活性。方法以γ-丁内酯为起始原料,经环合、氯代、取代、硫醚化和氨甲基化等反应合成7-苯基氨基-2-[3-(5-取代氨基甲基-呋喃-2-基-甲硫基)丙基]-5-甲基-[1,2,4]三氮唑并[1,5-a]嘧啶类化合物。采用MTT法,以顺铂为阳性对照药,以Bel-7402和HT-1080为测试细胞株对目标化合物的抗肿瘤活性进行了评价。结果与结论合成了12个未见文献报道的新化合物,结构经质谱、红外光谱和核磁共振氢谱确证。体外活性实验表明:化合物16显示出很好的抗肿瘤活性。     

5,7-二取代吡唑并[1,5-α]嘧啶类化合物的合成及其抗肿瘤活性

目的设计并合成吡唑并[1，5-α]嘧啶类化合物，并评价其抗肿瘤活性。方法根据吡唑并[1，5-α]嘧啶类抗肿瘤药物的基本结构，设计了14个5-胺甲基一7一苯胺基吡唑并[1，5-α]嘧啶类化合物，并以丙二腈和原甲酸三乙酯为起始原料，经5步反应得到目标产物。采用MTT法，顺铂为阳性对照药，以Bel-7402和HT-1080为测试细胞株对目标化合物进行抗肿瘤活性评价。结果与结论合成了14个未见文献报道的新化合物，结构经MS、IR和1H-NMR确证。体外活性实验表明：化合物12显示出较好的抗癌活性。     

7-芳胺基-3-氰基-5-烷基吡唑并[1,5-a]嘧啶类化合物的合成及药理活性

目的设计并合成7-芳胺基-3-氰基-5-烷基吡唑并[1,5-a]嘧啶类化合物,初步评价其药理活性。方法以丙二腈和原甲酸三乙酯为起始原料,通过新的合成路线制备了目标化合物;采用MTT法测定目标化合物的细胞毒性。结果与结论合成了13个新化合物,其结构经1H-NMR、MS确证,7个化合物显示出不同程度的细胞毒性,化合物8a、8f、8g的活性较好,有进一步研究的价值。     

7-芳胺基-3-氰基-5-烷基吡唑并[1,5-a]嘧啶类化合物的合成

目的 设计并合成7-芳胺基-3-氰基-5-烷基吡唑并[1,5-a]嘧啶类化合物,初步评价其药理活性.方法 以丙二腈和原甲酸三乙酯为起始原料,通过新的合成路线制备了目标化合物;采用MTT法测定目标化合物的细胞毒性.结果 与结论合成了13个新化合物,其结构经1H-NMR、MS确证,7个化合物显示出不同程度的细胞毒性,化合物8a、8f、8g的活性较好,有进一步研究的价值.     

靶向 Trk 抗肿瘤药物 larotrectinib 的新合成方法

目的改进抗肿瘤药larotrectinib的合成路线。方法以4-氯丁酰氯和N,O-二甲基羟胺盐酸盐为起始原料,经取代、格氏交换、缩合、还原、环合、成盐得到2R-(2,5-二氟苯基)吡咯烷,其与5-氯吡唑并[1,5-a]嘧啶反应得到中间体(R)-5-(2-(2,5-二氟苯基)吡咯烷-1-基)吡唑并[1,5-a]嘧啶,该中间体经硝化、还原后再与(S)-3-羟基吡咯烷盐酸缩合得到目标物larotrectinib。结果与结论合成larotrectinib的总收率为13.3%(以N,O-二甲基羟胺盐酸盐计),目标物及关键中间体的结构经MS、~1H-NMR谱确证。与原研专利路线相比,新合成路线使用了廉价易得的原料,提高了反应收率,优化了反应条件,可为工业化生产提供参考。     

新型乙酰胆碱酯酶抑制剂5H-噻唑并[3,2-a]嘧啶类化合物的设计、合成与生物活性研究

目的 寻找作为乙酰胆碱酯酶抑制剂的具有新化学结构类型的化合物。方法 采用分子对接的虚拟筛选方法寻找新型乙酰胆碱酯酶抑制剂，设计了10个5H-噻唑并[3,2-a]嘧啶类化合物。以芳醛、硫脲等为起始原料，通过Biginelli反应生成二氢嘧啶类化合物，再与氯代苯乙酮作用经Hantzsch环合反应制得目标化合物，其结构经红外光谱、质谱、核磁共振氢谱和碳谱确证。采用Ellman方法进行体外抑制乙酰胆碱酯酶活性测试。 结果 合成了10个5H-噻唑并[3,2-a]嘧啶类化合物，体外抑制乙酰胆碱酯酶活性测试结果显示，所有目标化合物均具有乙酰胆碱酯酶抑制活性，其中3个目标化合物在10 μmol.L^-1时抑制活性均超过50%。结论5H-噻唑并[3,2-a]嘧啶类化合物是潜在的乙酰胆碱酯酶抑制剂。将计算机辅助药物分子设计、有机合成和生物活性测试相结合是发现和设计新型乙酰胆碱酯酶抑制剂的有效途径。     

《中国药物化学杂志》2007年第17卷第1期～第6期(总75～80期)总目次

研究论文2,2-二甲基-1,3-二氧戊环-4,5-二羧酸衍生物的设计、合成及其神经营养活性………………………任,聂爱华,肖军海,等(1)(1)含哌嗪环的三唑醇类化合物的合成及体外抗真菌活性………………………………………………何秋琴,刘超美,李科,等(1)(8)β-榄香烯醇酯类化合物的合成及抗癌活性研究…………………………………………………………张兴忠,徐莉英,陶淑娟,等(1)(13)5,7-二取代吡唑并[1,5-a]嘧啶类化合物的合成及其抗肿瘤活性……………………………………李冶,刘亚婧,袁孝烨,等(1)(18)卟啉树状大分子化合物的合成及其抗活性氧作用……     

1,4-二氢噻吩并[3',2':5,6]噻喃并[4,3-c]吡唑-3-羧酸衍生物的合成及抗癌活性研究(英文)

本文以2-巯基噻吩为原料,经6步反应合成了5个1,4-二氢噻吩并[3',2':5,6]噻喃并[4,3-c]吡唑-3-羧酸衍生物,并采用人乳腺癌细胞MCF-7对目标化合物的抗肿瘤活性进行初步评价。所合成化合物在100μM浓度下均有一定的抑制MCF-7活性。     

Reactions with heterocyclic amidines (VI): Synthesis of some new sym. and assym. pyrazolotriazines and pyrazolo[4,5-e]pyrimidine derivatives

Several new pyrazolo[1,5-a]-S-triazine, pyrazolo[4,5-e]pyrimidine, pyrazolo [1,5-a]pyrimidine derivatives were synthesizedvia condensation of 3-antipyrinyl-5-aminopyrazole (2) with β-bifunctional reagents. The azo analogues of pyrazolo[1,5-a] pyrimidines;i.e pyrazolo[5,1-c]-as-triazine and pyrazolo[5,1-c]-as-benzotriazine were synthesized by coupling of diazotized 2 with agents containing active hydrogen.     

Synthesis and antiproliferative activity in vitro of new derivatives of 3-aminopyrazolo[3,4-b]pyridine. Part 1. Reaction of 3-aminopyrazolo[3,4-b]pyridine with 1,3-, 1,4-diketones and alpha,beta-unsaturated ketones

The synthesis of several new pyrazolo[3,4-b]pyridine, pyrido[2',3':3,4]-pyrazolo[1,5-a]pyrimidine and imidazo[1',2':1,5]pyrazolo[3,4-b]pyridine derivatives is described. The obtained compounds were tested for their antiproliferative activity in vitro. One of them, 4-phenyl-2-(3,4,5-trimethoxy-beta-styrylo)pyrido- [2',3':3,4]pyrazolo[1,5-a]pyrimidine (9), revealed cytotoxic properties against the cells of all three human cancer cell lines applied. Another one, 2,4-dimethyl-pyrido[2',3':3,4]pyrazolo[1,5-a]-pyrimidine (2), revealed weak cytotoxic activity only against the cells of human bladder cancer cell line HCV29T. All other compounds tested did not reveal any cytotoxic activity.     

Synthesis and anti-tumor activities of novel pyrazolo[1,5-a]pyrimidines

A series of novel pyrazolo[1,5-a]pyrimidines were designed and synthesized in order to find novel potent anti-tumor compounds. The structures of all the compounds were confirmed by IR, (1)H-NMR, elemental analysis, and MS. Their anti-tumor activities against cancer cell lines were tested by the MTT method in vitro. Compound 19 displayed potent anti-tumor activity.     

Studies on condensed-heterocyclic azolium cephalosporins. II. Synthesis and antibacterial activity of 7 beta-[2-(2-aminothiazol-4-yl)-2(Z)-alkoxyiminoacetamido]-3-(condensed- heterocyclic azolium)methyl-3-cephem-4-carboxylates.

From our series of studies on cephalosporins bearing condensed-heterocyclic azolium methyl groups at the 3 position in the cephalosporin nucleus, we describe here the synthesis and antibacterial activity of 7 beta-[2-(2-aminothiazol-4-yl)-2(Z)-alkoxyiminoacetamido]ceph alosporins containing imidazo[1,5-a]pyridinium, imidazo[1,2-b]pyridazinium, imidazo[1,2-a]pyrimidinium, imidazo[1,2-c]pyrimidinium, and pyrazolo[1,5-a]pyridinium methyl groups at the 3 position. Among the cephalosporins tested, 7 beta-[2-(2-aminothiazol-4-yl)-2(Z)-methoxyiminoacetamido]-3- (imidazo[1,5-a]pyridinium-2-yl) (1), (imidazo[1,2-b]pyridazinium-1-yl) (2), and (pyrazolo[1,5-a]-pyridinium-1-yl) (3)methyl-3-cephem-4-carboxylates showed potent antibacterial activity and broad antibacterial spectrum. The antibacterial activity of these cephalosporins (1 approximately 3) was superior to that of ceftazidime (CAZ). These results imply that the delocalization of the positive charge of the imidazo[1,5-a]pyridinium, pyrazolo[1,5-a]pyridinium and imidazo[1,2-b]pyridazinium groups leads to an expanded antibacterial spectrum and increased activity and that these condensed-heterocyclic compounds as well as imidazo[1,2-a]pyridine are effective moieties for improving antibacterial activity and spectrum.     

Cyclin-dependent kinase inhibitors inspired by roscovitine: purine bioisosteres

Roscovitine is a synthetic inhibitor of cyclin-dependent kinases that is currently undergoing clinical trials as a candidate drug for some oncological indications. Its discovery prompted many research teams to further optimize its structure or to initiate their own related but independent studies. This article reviews known roscovitine bioisosteres that have been prepared as CDK inhibitors using different core heterocycles. The individual bioisostere types have been described and explored to a different extent, which complicates direct comparisons of their biochemical activity - only six direct analogs containing different purine bioisosteres have been prepared and evaluated side by side with roscovitine. Only four types of bioisosteres have demonstrated improved biological properties, namely pyrazolo[ 1,5-a]-1,3,5-triazines, pyrazolo[1,5-a]pyrimidines, pyrazolo[1,5-a]pyridines and pyrazolo[4,3-d]pyrimidines.     

Impurity profile study of zaleplon

Zaleplon is a pyrazolopyrimidine derivative and possesses sedative and hypnotic properties. Seven unknown impurities in zaleplon bulk drug at levels below 0.1% were detected by reverse-phase high performance liquid chromatography (HPLC). The starting material, 3-amino-4-cyanopyrazole and an intermediate, N-[3-[3-(dimethylamino)-1-oxo-2-propenyl]-phenyl]-N-ethylacetamide (DOPEA) were also present in the sample at a level below 0.1%. The molecular weights of impurities were determined by LC-MS analysis. These impurities were isolated from crude samples of zaleplon using reverse-phase preparative HPLC. Based on the spectral data the structures of these impurities were characterized as, N-(3-(3-(4-amino-2H-pyrazolo [3,4-d]pyrimidin-6-yl) pyrazolo[1,5-a] pyrimidin-7-yl)phenyl)-N-ethylacetamide (impurity I); N-[3-(3-carboxamidopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide (impurity II); N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]acetamide (impurity III); N-[3-(3-cyanopyrazolo [1,5-a]pyrimidin-7-yl)phenyl]-N-methylacetamide (impurity IV); N-[3-(3-cyanopyrazolo[1,5-a] pyrimidin-5-yl)phenyl]-N-ethylacetamide (impurity V); N-[3-(3-cyanopyrazolo[1,5-a] pyrimidin-7-yl)phenyl]-N-ethylamine (impurity VI); N-[3-(3-cyano-6-[(E)-3-((N-ethyl-N-acetyl)amino)phenyl-3-oxoprop-1-enyl] pyrazolo[1,5-a]pyrimidin-7-yl) phenyl]-N-ethylacetamide (impurity VII). Structural elucidation of all impurities by spectral data ((1)H NMR, (13)C NMR, MS and IR) and formation of these impurities are discussed in detail.     

Azaindol derivatives. II. Synthesis and analgesic activity of pyrazol[1,5-a]pyridines

Azaindol-Derivatives II Synthesis and Analgesic Activity of Pyrazolo[1,5a]pyridines Reactions of the azaindolecarboxylicester 2 affords pyrazolo[1,5-a]pyridines, including 8-azatryptamine 8b , with various analgesic activities (ED₅₀-values: 8.2–140 mg/kg, writhing test). The inactive hydrogenation product 10 was prepared starting from 2 .     

Studies on Heterocyclic Amidines: Synthesis of New Azaindene Derivatives

Several new pyrazolo1,5-a]pyrimidines and pyrazolo[5,1-c]- 1,2,4-triazine derivatives were synthesised from 3(5)-aminopyrazoles 1a, b as starting components.     

Studies on aminopyrazoles: antibacterial activity of some novel pyrazol

Hydrazones 2a-d were prepared from diazotiazation of sulfanilamide or its derivatives followed by coupling with ethyl cyanoacetate. 3-Aminopyrazoles 3a-d were obtained by refluxing of 2a-d with hydrazine hydrate in ethanol. [Bis(-methylthio)methylene]malononitrile (4) was reacted with aminopyrazoles 3a-d in refluxing DMF containing triethylamine to yield the novel pyrazolo[1,5-a]pyrimidines 6a-d. The anilino derivatives 8a-h were obtained by fusion of compounds 6a-d with aromatic amines. When compounds 6a,c,d were subjected to the reaction with hydrazine hydrate, the hydrazino derivatives 9a-c were isolated. Also, the aminopyrazoles 3 were reacted with some electrophiles such as arylidenemalononitriles, ethoxymethylene malononitrile and ethyl ethoxymethylene cyanoacetate to yield the novel substituted pyrazolo[1,5-a]pyrimidines 13, 17 and 19, respectively. Structures of the new compounds were established by their elemental analyses and spectral data. Most of these compounds were also tested in vitro for their antibacterial activity against some gram positive and gram negative bacteria.